Developing Next Generation Gene Therapies

Splice Bio is a biotech company based on intein technologies developed in the Muir Lab at Princeton University. We are working with our proprietary platform to address key limitations of current gene therapy approaches to treat patients in need.

SPLICE BIO APPOINTS JEAN-PHILIPPE COMBAL AS CHAIRMAN OF THE BOARD OF DIRECTORS

BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed Jean-Philippe Combal as Chairman of its Board of Directors. Dr. Combal is a proven senior executive and biotechnology entrepreneur with 30 years of experience in the pharma & biotech industry and particularly in the field of gene therapy.

Read the Press Release

SPLICE BIO ANNOUNCES RESEARCH FUNDING BY CYSTIC FIBROSIS FOUNDATION TO DEVELOP NOVEL AAV VECTORS

BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis Foundation to develop novel adeno-associated viruses (AAVs) aimed at treating people suffering from cystic fibrosis (CF). The Company will receive up to $343,000 in research funding to advance its proprietary 3rd-generation intein platform and develop novel AAVs better suited to target specific cells in the lungs of people with CF.

Read the Press Release

SPLICE BIO AWARDED WITH A “RETOS DE COLABORACIÓN” GRANT

BARCELONA, October 20, 2020 – Splice Bio, a biotech company based on technology developed in the Muir lab at Princeton University, announced today that it has been awared a “RETOS-Colaboración” grant from the Spanish Ministry of Science and Innovation (RTC2019-006879-1).

Read the Press Release

PROTEODESIGN ANNOUNCES NEW INVESTMENT LED BY YSIOS CAPITAL AND REBRANDS AS SPLICE BIO

  • ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology.

  • This pioneering platform has the potential to target genetic diseases that cannot be addressed with current gene therapies.

  • Ysios and Asabys join the board of directors as new investors

BARCELONA, September 15, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partners from its fund Sabadell Asabys. This financing round was organized thanks to the support of existing shareholder Caixa Capital Risc. ProteoDesign is rebranding as Splice Bio to reflect on its progress with its proprietary intein platform, based on pioneering research by the company’s co-founders, and its new focus on gene therapy.

Read the Press Release

MANAGEMENT TEAM

Miquel Vila-Perelló, PhD

FOUNDER & CEO

Silvia Frutos, PhD

FOUNDER & CTO

Gerard Caelles

CHIEF BUSINESS OFFICER

Private investors
Public Funding
Public Funding
Public Funding
Certification

Tel. +34 93 402 04 56

© Splice Bio

info@splice.bio